VINZENZ GRUPPE
     
 

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.

Ferenci, Peter und Laferl, Hermann und Scherzer, Thomas-Matthias und Maieron, Andreas und Hofer, Harald und Stauber, Rudolf und Gschwantler, Michael und Brunner, Harald und Wenisch, Christoph und Bischof, Martin und Strasser, Michael und Datz, Christian und Vogel, Wolfgang und Löschenberger, Karin und Steindl-Munda, Petra (2010) Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology, 138 (2). 503-12, 512.e1. ISSN 1528-0012

Für diesen Eintrag wurde kein Volltext-Dokument angefügt.

Kurzfassung

BACKGROUND & AIMS This randomized multicenter trial evaluated individualization of treatment duration with peginterferon alfa-2a 180 microg/wk plus ribavirin 1000/1200 mg/day in patients with chronic hepatitis C genotype 1/4 based on the rapidity of virologic response (VR). METHODS Patients with a rapid VR (RVR; undetectable hepatitis C virus [HCV]-RNA level (<50 IU/mL at week 4) were treated for 24 weeks, those with an early VR (EVR; no RVR but undetectable HCV-RNA level or >or=2-log(10) decrease at week 12) were randomized to 48 (group A) or 72 weeks of treatment (group B; peginterferon alfa-2a was reduced to 135 microg/wk after week 48). Patients without an EVR continued treatment until week 72 if they had undetectable HCV-RNA levels at week 24. The primary end point was relapse; sustained VR (SVR; undetectable HCV-RNA level after 24 weeks of follow-up evaluation) was a secondary end point. RESULTS Of 551 genotype 1/4 patients starting treatment, 289 were randomized to group A (N = 139) or group B (N = 150). The relapse rate was 33.6% in group A (95% confidence interval [CI], 24.8%-43.4%) and 18.5% in group B (95% CI, 11.9%-27.6%; P = .0115 vs group A) and the SVR rate was 51.1% (95% CI, 42.5%-59.6%) and 58.6% (95% CI, 50.3%-66.6%; P > .1), respectively. The overall SVR rate was 50.4% (278 of 551; 95% CI, 46.2%-54.7%), including 115 of 150 patients with an RVR treated for 24 weeks and 4 of 78 patients without an EVR. CONCLUSIONS Extending therapy with peginterferon alfa-2a/ribavirin to 72 weeks decreases the probability of relapse in patients with an EVR. If they can be maintained on extended-duration therapy, SVR rates also may improve.
Typ des Eintrags: Artikel
Bereiche: Ordensklinikum Linz Barmherzige Schwestern > Interne IV: Gastroenterologie & Hepatologie, Endokrinologie und Stoffwechsel, Ernährungsmedizin
Benutzer: Prof. Dr. Rainer Schöfl
Hinterlegungsdatum: 16 Nov 2021 11:40
Letzte Änderung: 17 Feb 2025 09:34
URI: https://eprints.vinzenzgruppe.at/id/eprint/9371
Aktionen (Anmeldung erforderlich)
Eintrag anzeigen
Eintrag anzeigen